# Neurogene (NGNE) — Analyst Forecast

NGNE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ngne/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 0 | 0 | 10 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $60.00 | $93.00 | $166.00 | 4 |

Last price $23.95 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 8, 2026 | JP Morgan | Initiated Coverage | Overweight | $60.00 |
| Aug 12, 2026 | HC Wainwright & Co. | Maintained | Buy | $65.00 |
| Aug 12, 2026 | Guggenheim | Maintained | Buy | $81.00 |
| Aug 12, 2026 | Canaccord Genuity | Maintained | Buy | $166.00 |
| Jun 9, 2026 | HC Wainwright & Co. | Maintained | Buy | $70.00 |
| Apr 6, 2026 | Canaccord Genuity | Maintained | Buy | $180.00 |
| Feb 27, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $200.00 |
| Jan 26, 2026 | LifeSci Capital | Initiated Coverage | Outperform | $50.00 |
| Jan 13, 2026 | HC Wainwright & Co. | Maintained | Buy | $70.00 |
| Nov 13, 2025 | HC Wainwright & Co. | Maintained | Buy | $70.00 |
| Oct 31, 2025 | HC Wainwright & Co. | Maintained | Buy | $65.00 |
| Oct 9, 2025 | HC Wainwright & Co. | Maintained | Buy | $45.00 |
| Jun 17, 2025 | Craig-Hallum | Initiated Coverage | Buy | $50.00 |
| Jun 12, 2025 | BMO Capital | Maintained | Outperform | $26.00 |
| May 20, 2025 | BMO Capital | Maintained | Outperform | $22.00 |
| May 16, 2025 | Baird | Downgraded | Outperform → Neutral | $24.00 |
| May 13, 2025 | HC Wainwright & Co. | Maintained | Buy | $45.00 |
| Apr 14, 2025 | BMO Capital | Maintained | Outperform | $16.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Maintained | Buy | $50.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Maintained | Buy | $55.00 |

## Frequently Asked Questions

### What is the price target for NGNE stock?

The average 12-month analyst price target for Neurogene (NGNE) is $93.00, with a high estimate of $166.00 and a low of $60.00, across 4 analysts.

### Is NGNE a buy, sell, or hold?

Analysts covering Neurogene currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for NGNE?

The average price target of $93.00 implies 288.31% upside from the last price of $23.95.

### What is the latest analyst rating on NGNE?

On Oct 8, 2026, JP Morgan initiated coverage of Neurogene at Overweight with a price target of $60.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).